Regulation of monoamine transporters: Role of transporter phosphorylation

被引:97
作者
Ramamoorthy, Sammanda [1 ]
Shippenberg, Toni S. [2 ]
Jayanthi, Lankupalle D. [1 ]
机构
[1] Med Univ S Carolina, Div Neurosci Res, Dept Neurosci, Charleston, SC 29425 USA
[2] Natl Inst Drug Abuse, Integrat Neurosci Sect, Intramural Res Program, NIH,US Dept Hlth & Human Serv, Baltimore, MD 21224 USA
基金
美国国家卫生研究院;
关键词
Biogenic amines; Transporters; Regulation; Phosphorylation; Mental illness; PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; HUMAN SEROTONIN TRANSPORTER; HUMAN NOREPINEPHRINE TRANSPORTER; TRAFFICKING-INDEPENDENT REGULATION; INDUCED REVERSE TRANSPORT; CELL-SURFACE EXPRESSION; MICE LACKING; FUNCTIONAL REGULATION; PLASMA-MEMBRANE;
D O I
10.1016/j.pharmthera.2010.09.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Presynaptic biogenic amine transporters mediate reuptake of released amines from the synapse, thus regulating serotonin, dopamine and norepinephrine neurotransmission. Medications utilized in the treatment of depression, attention deficit-hyperactivity disorder and other psychiatric disorders possess high affinity for amine transporters. In addition, amine transporters are targets for psychostimulants. Altered expression of biogenic amine transporters has long been implicated in several psychiatric and degenerative disorders. Therefore, appropriate regulation and maintenance of biogenic amine transporter activity is critical for the maintenance of normal amine homoeostasis. Accumulating evidence suggests that cellular protein kinases and phosphatases regulate amine transporter expression, activity, trafficking and degradation. Amine transporters are phosphoproteins that undergo dynamic control under the influence of various kinase and phosphatase activities. This review presents a brief overview of the role of amine transporter phosphorylation in the regulation of amine transport in the normal and diseased brain. Understanding the molecular mechanisms by which phosphorylation events affect amine transporter activity is essential for understanding the contribution of transporter phosphorylation to the regulation of monoamine neurotransmission and for identifying potential new targets for the treatment of various brain diseases. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:220 / 238
页数:19
相关论文
共 270 条
[1]   Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching [J].
Adkins, Erika M. ;
Samuvel, Devadoss J. ;
Fog, Jacob U. ;
Eriksen, Jacob ;
Jayanthi, Lankupalle D. ;
Vaegter, Christian Bjerggaard ;
Ramamoorthy, Sammanda ;
Gether, Ulrik .
BIOCHEMISTRY, 2007, 46 (37) :10484-10497
[2]   INCREASED IMPULSIVE BEHAVIOR AND RISK PRONENESS FOLLOWING LENTIVIRUS-MEDIATED DOPAMINE TRANSPORTER OVER-EXPRESSION IN RATS' NUCLEUS ACCUMBENS [J].
Adriani, W. ;
Boyer, F. ;
Gioiosa, L. ;
Macri, S. ;
Dreyer, J. -L. ;
Laviola, G. .
NEUROSCIENCE, 2009, 159 (01) :47-58
[3]   The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice [J].
Ahern, TH ;
Javors, MA ;
Eagles, DA ;
Martillotti, J ;
Mitchell, HA ;
Liles, LC ;
Weinshenker, D .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (04) :730-738
[4]   Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes [J].
Amenta, F ;
Bronzetti, E ;
Cantalamessa, F ;
El-Assouad, D ;
Felici, L ;
Ricci, A ;
Tayebati, SK .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 117 (1-2) :133-142
[5]   ACTIVATORS OF PROTEIN-KINASE-C DECREASE SEROTONIN TRANSPORT IN HUMAN PLATELETS [J].
ANDERSON, GM ;
HORNE, WC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1137 (03) :331-337
[6]   Involvement of threonine 258 and serine 259 motif in amphetamine-induced norepinephrine transporter endocytosis [J].
Annamalai, Balasubramaniam ;
Mannangatti, Padmanabhan ;
Arapulisamy, Obulakshmi ;
Ramamoorthy, Sammanda ;
Jayanthi, Lankupalle D. .
JOURNAL OF NEUROCHEMISTRY, 2010, 115 (01) :23-35
[7]   Calcium-dependent inhibition of synaptosomal serotonin transport by the α2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6-quinoxalinamine (UK14304) [J].
Ansah, TA ;
Ramamoorthy, S ;
Montañez, S ;
Daws, LC ;
Blakely, RD .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03) :956-965
[8]  
Apparsundaram S, 2001, J PHARMACOL EXP THER, V299, P666
[9]  
Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733
[10]  
Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744